


Neurodegenerative diseases such as Alzheimer's affect over 7 million people in Europe. Despite this fact, few treatments for this group of diseases are available so far. Nanomedical approaches can make a difference, providing new therapeutic options by helping drugs to enter the brain. The overall objective of B-SMART is to create brain-targeted RNA-based nanomedicines for neurodegenerative diseases that are manufactured via a quality-by-design approach with precise nanoparticle characterization and specifications that meet the requirements for GMP scaling up and clinical translation.

The RNA delivery system is based on three essential components which can only be successful if combined:



The goal is to manufacture the modular nanoparticles using a microfluidic assembly system that will ensure quality-by-design, to test pre-clinical activity of formulations with promising in vitro activity with good cell/blood compatibility and to select the best RNA-formulation for clinical translation to treat neurodegenerative diseases.



Contact:

Coordinator

University Medical Center Utrecht
Prof. Raymond Schiffelers
Email: R.Schiffelers@umcutrecht.nl

Project Management

EURICE – European Research and Project Office GmbH
Dr Silke von Sehlen
Email: S.vonSehlen@eurice.eu